ClinicalTrials.gg
TerminatedNCT07076550Updated Aug 31, 2026

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

A Phase 1 interventional study of [225Ac]Ac-A9-3408 and [68Ga]Ga-A9T-3202 in Melanoma Metastatic, Uveal Melanoma, Metastatic and Mucosal Melanoma, sponsored by Alpha-9 Oncology USA Inc.. Terminated at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Alpha-9 Oncology USA Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to a strategic decision to re-prioritize the sponsor's existing portfolio.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Uveal Melanoma with a site in Australia — 8 open to participants now, 15 under way, 5 of them phase 3. Uveal Melanoma · Australia.

Enrollment
20th of 20
5 · median 108
Started
2025
with 3 others
Phase 1
7 of 22
2 open now
Registered
19th of 22
by date
Lead sponsor
1 of 22
Alpha-9 Oncology USA Inc.

Among the 22 studies in Uveal Melanoma with a site in Australia, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 1, and was the 19th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

8 of the 22 studies in Uveal Melanoma with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Australia, or all of them as a file.
02

Study summary

The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. The main questions this study aims to answer are:

  • What are the side effects of this investigational drug?
  • What is the highest dose of this investigational drug that can be given safely?

Participants will:

  • Take the investigational drug once every 6 weeks, for up to 6 times in total
  • Visit a doctor's office on a regular basis for checkups and tests
Read the detailed description

This is a multicenter, open-label Phase 1-1b study of [225Ac]Ac-A9-3408 in subjects with unresectable or metastatic melanoma.

The primary aim of the Phase 1 portion of the study is to evaluate the safety and tolerability as well as the normal organ and tumor dosimetry of [225Ac]Ac-A9-3408 and to select a recommended Phase 2 dose (RP2D).

The aim of Phase 1b will be to evaluate the safety, efficacy, and normal organ and tumor dosimetry of [225Ac]Ac-A9-3408 administered at the RP2D in subjects with unresectable or metastatic cutaneous melanoma who had confirmed disease progression while receiving an anti-PD-1/PD-L1-containing regimen.

The interventional diagnostic [68Ga]Ga-A9T-3202 will be administered intravenously (IV) once during screening.

The interventional drug [225Ac]Ac-A9-3408 will be administered intravenously (IV) once every 6 weeks, for a total of up to 6 cycles.

03

Conditions studied

  • Melanoma Metastatic
  • Uveal Melanoma, Metastatic
  • Mucosal Melanoma

Keywords

  • Metastatic Melanoma
  • Melanoma
  • Radiopharmaceuticals
  • Theranostic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written
  • [68Ga]Ga-A9T-3202 uptake in at least one (per v1.1) on PET scan
  • or cytologically confirmed unresectable or melanoma with disease progression on prior standard of care therapy
  • Adequate performance status
  • Adequate baseline organ function within 14 days of first dose of product
  • Recovered from side effects of prior anticancer therapy
  • Women of (WOCBP) must have a negative pregnancy test and follow adequate method(s) during the treatment period and for at least 6 months after last dose of [225Ac]Ac-A9-3408. Sexually active males with partners who are WOCBP must agree to adequate birth control method(s) during the treatment period and for at least 3 months after last dose of [225Ac]Ac-A9-3408

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with radioactive nuclides except radioactive imaging tracers
  • Treatment with another product shortly prior to first dose of [225Ac]Ac-A9-3408 with exception of /PD-L1 agents.
  • Concurrent anticancer therapy
  • Major surgery within 4 weeks of first dose of investigational product
  • Second within 2 years
  • Active, clinically serious infection
  • Known infusion reactions to components of the investigational product
  • Other clinically serious health conditions including cardiovascular and or severe infectious diseases
  • Significant central nervous system disease
  • Pregnant, breastfeeding or unwilling to practice adequate method(s)
  • Any condition per the opinion of the investigator that would impact the safety of the subject, protocol adherence or ability to provide
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Escalation

    Participants enrolled in Dose Escalation will receive a single dose of the investigational diagnostic agent \[68Ga\]Ga-A9T-3202 during screening, and receive the investigational treatment \[225Ac\]Ac-A9-3408 once every 6 weeks, for up to 6 total cycles.

    Drug: [225Ac]Ac-A9-3408 · Diagnostic Test: [68Ga]Ga-A9T-3202

  • Experimental
    Phase 1B Dose Expansion

    Participants enrolled in Dose Expansion will receive a single dose of the investigational diagnostic agent \[68Ga\]Ga-A9T-3202 during screening, and receive the investigational treatment \[225Ac\]Ac-A9-3408 once every 6 weeks, for up to 6 total cycles.

    Drug: [225Ac]Ac-A9-3408 · Diagnostic Test: [68Ga]Ga-A9T-3202

Interventions

06

What researchers measure

Primary outcomes

  1. Determine max tolerated dose and recommended Phase 2 Dose

    Rate of DLTs per dose level/cohort

    Time frame: First 28 days following first study treatment

  2. Incidence of treatment-related adverse events

    Rate and severity of suspected treatment-related adverse events, change from baseline laboratory values and change from baseline vital signs as graded by CTCAE version 5.0

    Time frame: From first study treatment until end of treatment

Secondary outcomes

  1. Evaluate the preliminary efficacy of [225Ac]Ac-A9-3408 by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Percent of patients who achieve an overall response (ORR), defined as the percent of patients who achieve a complete response (CR) or partial response (PR) by RECIST v1.1

    Time frame: Up to 1 year from enrollment

  2. Evaluate biodistribution and normal organ dosimetry of [225Ac]Ac-A9-3408

    Absorbed radiation dose estimates (Gy) in normal organs for \[225Ac\]Ac-A9-3408

    Time frame: Up to 7 days following each cycle (42 days)

07

Study locations

4 sites
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Austin Health
    Melbourne, Victoria 3084, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • GenesisCare Murdoch
    Murdoch, Western Australia 6150, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jul 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 22, 2025
StartActual
Nov 19, 2025
Primary completionActual
Jul 9, 2026
CompletionActual
Jul 9, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076550
Lead sponsor
Alpha-9 Oncology USA Inc.
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Nov 19, 2025
Primary completion
Jul 9, 2026
Completion
Jul 9, 2026
Last update
Aug 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion